← Back to Clinical Trials
Recruiting NCT07364331

NCT07364331 Omega-3 Fatty Acids, Neuroendocrine and Attention Deficit Hyperactivity Disorder (OMNeADHD)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07364331
Status Recruiting
Phase
Sponsor China Medical University Hospital
Condition ADHD
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2021-09-04
Primary Completion 2026-07-31

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
Omega-3Placebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2021-09-04 with a primary completion date of 2026-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a 12 week randomized controlled study on the effects of omega-3 fatty acids in youth with attention deficit hyperactivity disorder (ADHD) with omega-3 deficiency.

Eligibility Criteria

Inclusion Criteria: 1. DSM-5 diagnosis of ADHD 2. Did not have any changes of ADHD treatment (pharmacological/psychological) within 4 weeks of entering the trial. 3. SNAP-IV inattention subscale \>=12, or hyperactivity subscale \>=12, or inattention+ hyperactivity subscales \>=24 Exclusion Criteria: 1. IQ\<80 2. Allergic to omega-3 3. Physical disorders: thyroid function, cancer 4. Psychiatric comorbidity: SUD, psychotic disorders, bipolar disorder, major depressive disorder

Contact & Investigator

Central Contact

Pei-Chen Chang, PhD

✉ 013121@tool.caaumed.org.tw

📞 +88622052121

Principal Investigator

Pei-Chen Chang, PhD

PRINCIPAL INVESTIGATOR

China Medical University Hospital

Frequently Asked Questions

Who can join the NCT07364331 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, up to 18 Years, studying ADHD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07364331 currently recruiting?

Yes, NCT07364331 is actively recruiting participants. Contact the research team at 013121@tool.caaumed.org.tw for enrollment information.

Where is the NCT07364331 trial being conducted?

This trial is being conducted at Taichung, Taiwan.

Who is sponsoring the NCT07364331 clinical trial?

NCT07364331 is sponsored by China Medical University Hospital. The principal investigator is Pei-Chen Chang, PhD at China Medical University Hospital. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology